Related Experiment Videos
Antihypertensive therapy and the risk of coronary heart disease
Insights
Certain hypertension drugs, like diuretics, can negatively impact cholesterol and triglyceride levels. Therapies that do not affect glucose metabolism appear to be the best choice for managing hypertension and preventing heart disease.
Area of Science:
- Cardiology
- Pharmacology
- Metabolic Disorders
Background:
- Hypertension treatment often involves diuretics, which can alter lipid profiles.
- The impact of various antihypertensive drugs on serum lipids, including cholesterol and triglycerides, requires careful consideration.
- Existing treatments may counteract cardiovascular benefits through adverse lipid changes.
Purpose of the Study:
- To investigate the effects of different antihypertensive drugs on lipid and lipoprotein concentrations.
- To determine if antihypertensive therapies influence coronary heart disease risk through lipid alterations.
- To identify antihypertensive regimens with favorable lipid profiles for improved cardiovascular outcomes.
Main Methods:
- Analysis of serum total cholesterol, triglyceride, and high-density lipoprotein (HDL) cholesterol levels.
- Evaluation of lipid changes associated with specific diuretic drugs (thiazides, furosemide, spironolactone) and other agents (reserpine, methyldopa, beta-blockers).
- Correlation of lipid alterations with changes in glycohemoglobin and serum glucose.
Main Results:
- Diuretics can increase total cholesterol and triglycerides; thiazides maintain HDL cholesterol.
- Furosemide, spironolactone, reserpine, and methyldopa did not alter total cholesterol or triglycerides.
- Methyldopa reduced HDL cholesterol; furosemide increased the total to HDL cholesterol ratio. Combination therapies often worsened lipid profiles.
Conclusions:
- Antihypertensive drug-induced lipid changes can offset blood pressure control benefits for coronary heart disease (CHD) prevention.
- Therapies that do not disrupt glucose metabolism are likely to have a neutral effect on lipids.
- Regimens preserving normal glucose metabolism are preferred for hypertension management to mitigate CHD risk.
Abstract:
Diuretic drugs, when used in the treatment of hypertension, cause an increase in the serum concentration of total cholesterol and sometimes of triglyceride. High density lipoprotein (HDL) cholesterol remains stable with thiazide-type diuretic drugs. Treatment with furosemide, spironolactone, reserpine, and methyldopa does not affect serum total cholesterol or triglyceride concentrations. However, methyldopa decreases HDL cholesterol, and furosemide increases the ratio of total to HDL cholesterol. When reserpine, methyldopa, or beta-blocking drugs are added to diuretic therapy, triglyceride increases and HDL cholesterol decreases. The mechanism of the lipid-lipoprotein alterations is unknown, but the changes correlate with changes in glycohemoglobin and serum glucose noted during diuretic-based therapy. The changes in total cholesterol and HDL cholesterol caused by some antihypertensive agents counterbalance the benefits on the development of coronary heart disease (CHD) expected from the control of blood pressure. Thus, treatment regimens with a more favorable influence on serum lipids may be crucial to better control of CHD. In the quest for such regimens, our data suggest that therapy which does not disturb glucose metabolism is likely to be free of lipid effect, and, therefore, would qualify as preferred therapy for hypertension.